Biotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.
Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Kiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019.
https://european-biotechnology.com/wp-content/uploads/2024/04/robertfriesen.png541541h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-02-06 09:39:442019-02-06 09:39:44Kiadis Pharma appoints Dr. Robert Friesen as CSO
Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.
https://european-biotechnology.com/wp-content/uploads/2024/04/Jennewein.jpg7201080Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-02-06 07:47:072019-02-06 07:47:07Jennewein Biotechnologie expands into Chinese market
https://european-biotechnology.com/wp-content/uploads/2024/04/Orexin.jpg348562Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-02-05 08:16:172019-02-05 08:16:17Medicxi put €40m into two Sosei spin off companies
https://european-biotechnology.com/wp-content/uploads/2024/04/EMA__Nikolay_Litov_41991598_s.jpg551869Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-02-03 16:49:572019-02-03 16:49:57EMA greenlights two orphan drugs and two biosimilars
Hitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.
https://european-biotechnology.com/wp-content/uploads/2024/04/apceth-.jpg5071360Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-02-01 09:18:182019-02-01 09:18:18Hitachi expands European reach in cell and gene therapy
Industrial biotech hub validates start-up ideas
Latest Newsuniqure delivers POC for hemophilia B gene therapy
Latest NewsGene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Pharma gets clinical milestone for IL7R antagonist
Latest NewsOse Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.
How stroma cells trigger tumour angiogenesis
Latest NewsAnalyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Kiadis Pharma appoints Dr. Robert Friesen as CSO
AppointmentsKiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019.
Jennewein Biotechnologie expands into Chinese market
Latest NewsMedicxi put €40m into two Sosei spin off companies
Latest NewsSosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMA greenlights two orphan drugs and two biosimilars
Latest NewsEMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi expands European reach in cell and gene therapy
Latest NewsHitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.
Dewpoint Therapeutics kicks off with $60m financing
Latest NewsDewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.